|
Exchange: |
|
Security
Type: |
|
Shares
Out: |
67,210,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
|
Level
II Sector: |
|
Level
III Sector: |
|
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Gracell Biotechnologies is a holding company. Through its subsidiaries, Co. engages in discovering and developing cell therapies to resolve industry challenges and fulfill unmet medical needs in the treatment of cancer. Co.'s product candidates include: GC012F is a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate for the treatment of MM; GC019F is a FasTCAR-enabled CD19-directed autologous CAR-T product candidate for the treatment of adult B-ALL; GC027 is a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate for the treatment of adult T-ALL; and GC007g is a donor-derived CD19-directed allogeneic CAR-T cell therapy for the treatment of r/r B-ALL.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|